A medication used by millions (including off-label usage for “longevity” purposes) may alter the fundamental pathways responsible for exercise adaptation. This episode reviews new 2025 data showing reduced improvements in vascular insulin sensitivity, aerobic capacity, and glucose regulation when the medication is paired with structured training. We look at prior evidence of blunted mitochondrial respiration and diminished hypertrophy, along with 2020 transcriptomic findings that paint a more nuanced picture.The goal: clarify when this medication interferes with exercise-driven improvements in muscle, mitochondria, and vascular function, and when it may support resilience during aging.00:00 – Intro00:48 – The Rise of a “Longevity” Medication01:31 – New Clinical Data Challenges Expectations03:34 – Earlier Trials Showed the Same Pattern05:05 – Resolving the Apparent Contradiction07:10 – Who Should, and Shouldn’t, Use This MedicationPMID: 30548390PMID: 31557380PMID: 33071237PMID: 37928155

Ver todos los episodios